Skip to main content

Table 5 Treatment-related adverse events in HCC patients with Lenvatinib based combination treatment

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

Adverse Event Any Grade Grade I–II Grade III–V
Any adverse event 68/94.4% 49/68.5% 19/26.3%
Rash 7/9.7% 7/9.7% 0/0.00%
Diarrhea 13/18.1% 10/13.9% 3/4.2%
Anemia 23/31.9% 16/22.2% 7/9.7%
Elevate transaminase 28/38.9% 21/29.2% 7/9.7%
Hypertension 11/15.3% 8/11.1% 3/4.2%
Leukopenia 16/22.2% 12/16.7% 4/5.6%
Thyroid dysfunction 13/18.1% 13/18.1% 0/0.00%
Constipation 4/5.6% 4/5.6% 0/0.00%
Bleeding 8/11.1% 8/11.1% 0/0.00%
Vision loss 1/1.4% 1/1.4% 0/0.00%
Proteinuria 25/34.7% 25/34.7% 0/0.00%
Fever 2/2.8% 2/2.8% 0/0.00%
Fatigue 9/12.5% 9/12.5% 0/0.00%
Hand-foot skin reaction 10/13.9% 10/13.9% 0/0.00%
Decreased appetite 4/5.6% 4/5.6% 0/0.00%
Vomitting 3/4.2% 3/4.2% 0/0.00%
Bloody stools 1/1.4% 1/1.4% 0/0.00%
  1. Data are presented as n/%